Vi använder cookies för att din upplevelse av webbplatsen ska bli bättre. Genom att fortsätta använda vår webbplats accepterar du våra cookies. Läs mer om cookies. Jag förstår

Menu ProbarE

Menu

Läs sidan på svenska Read the page in English
  • Home
  • About ProbarE
    • Areas of expertise
    • Policy
  • Who we are
  • Studies
  • Other activities
  • Contact us
0732-300 450 E-post LinkedIn Instagram Facebook
Läs sidan på svenska Read the page in English

  • Does your child or teen suffer from moderate or severe migraine?
  • Do you have COPD and want to take part in a medical study?
  • Do you have COPD?
  • Does depression make you miss out on things?

Does your child or teen suffer from moderate or severe migraine?

Now enrolling: a clinical study to evaluate the safety and efficacy of a dissolving tablet called rimegepant in children and teens 12 to 17 years old with moderate or severe migraine. Rimegepant is approved by the US Food and Drug Administration (FDA) for the acute treatment of migraine in adults.

To be eligible for this study, participants must:

  • Be 12 to 17 years old
  • Have a history of migraine for 6 months or longer
  • Have a history of 1 to 8 moderate or severe migraine attacks (lasting more than 3 hours without treatment) per month during the past 2 months
  • Be able to understand the assent form and have parent(s)/caregiver(s) who can give informed consent

This is not a complete list of study requirements. The study doctor will review all requirements with you and your child or teen.

To learn more about this study, contact:

Ewa Karlsson, phone 0732-300 450 or email ewa.karlsson@probare.se

ProbarE i Lund AB

Lilla Fiskaregatan 10
222 22 Lund

Ring oss Tfn +46 (0)732-300 450
Ring oss Fax +46 (0)46-125 580
Ring oss E-mail

ProbarE i Stockholm AB

Vegagatan 8,
113 29 Stockholm

Ring oss Tfn  +46 (0)723-942 294
Ring oss E-mail

Social media

LinkedIn LinkedIn
Instagram Instagram
Instagram Facebook

ProbarE